Welcome to LookChem.com Sign In|Join Free

CAS

  • or

61848-66-6

Post Buying Request

61848-66-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

61848-66-6 Usage

Uses

[SP-4-2-(1R-trans)]-(1,2-Cyclohexanediamine-N,N’) dichloridoplatinum(II) is an impurity of Oxiplatin (O845075), third generation platinum complex. An antitumor agent with activity against colorectal cancer. Cytotoxicity follows the formation of adducts with DNA. Antineoplastic.

Check Digit Verification of cas no

The CAS Registry Mumber 61848-66-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,1,8,4 and 8 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 61848-66:
(7*6)+(6*1)+(5*8)+(4*4)+(3*8)+(2*6)+(1*6)=146
146 % 10 = 6
So 61848-66-6 is a valid CAS Registry Number.

61848-66-6 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • USP

  • (1481306)  Oxaliplatin System Suitability  United States Pharmacopeia (USP) Reference Standard

  • 61848-66-6

  • 1481306-25MG

  • 13,501.80CNY

  • Detail

61848-66-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name Platinum, dichloro(1,2-cyclohexanediamine-N,N')-, [SP-4-2-(1R-trans)]-

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:61848-66-6 SDS

61848-66-6Relevant articles and documents

In vitro and in vivoactivity of series of cationic dinuclearPt(II) complexes

Vasi?, Ivana,Rajkovi?, Sne?ana,Arsenijevi?, Aleksandar,Milovanovi?, Marija,Arsenijevi?, Neboj?a,Milovanovi?, Jelena,?ivkovi?, Marija D.

, (2021/10/01)

The antitumour potential of nine dinuclear platinum(II) complexes of the type [{Pt(L)Cl}2(μ-X)]2+(where L represents two NH3 or different bidentantly coordinated diamine ligand - ethylenediamine, en; (±)-1,2-propylenediamine, 1,2-pn; isobutylenediamine, ibn; trans-(±)-1,2-diaminocyclohexane, dach; 1,3-propylenediamine, 1,3-pd; 2,2-dimethyl-1,3-propylenediamine, 2,2-diMe-1,3-pd; (±)-1,3-pentanediamine,1,3-pnd, and X is a bridging pyrazine (pz) or pyridazine (pydz) ligand) were determined by in vitro and in vivo assays using the CT26 cell line and a murine model of heterotopic colon cancer tumour induced in immunocompetent BALB/c mice. This study concludes that complexes Pt1, Pt2 and Pt7 possess significant in vitro cytotoxic activity against mouse colon carcinoma CT26 cells, while all these complexes show moderate apoptotic effect. Complexes Pt1 and Pt7 arrested CT26 cells in G2/M phase of cell cycle, while, evaluated by detection of Ki67 expressing cells, complexes Pt5 and Pt6 exerted the highest antiproliferative effect. Complexes Pt1 and Pt2 exerted significant in vivo antitumour effects. These complexes reduced the growth of primary tumour and the incidence of lung and liver metastases without causing the significant hepato- and nephro- toxicity. Our data indicate considerable antitumour activity of platinum(II) complexes against CT26 cells in vitro and in vivo and imply possible further investigations on their role as potential chemotherapeutic agents.

Synthesis, cytotoxic activity and DNA interaction studies of new dinuclear platinum(ii) complexes with an aromatic 1,5-naphthyridine bridging ligand: DNA binding mode of polynuclear platinum(ii) complexes in relation to the complex structure

Konovalov, Bata,?ivkovi?, Marija D.,Milovanovi?, Jelena Z.,Djordjevi?, Dragana B.,Arsenijevi?, Aleksandar N.,Vasi?, Ivana R.,Janji?, Goran V.,Franich, Andjela,Manojlovi?, Dragan,Skrivanj, Sandra,Milovanovi?, Marija Z.,Djuran, Milo? I.,Rajkovi?, Sne?ana

, p. 15091 - 15102 (2018/11/10)

The synthesis, spectroscopic characterization, cytotoxic activity and DNA binding evaluation of seven new dinuclear platinum(ii) complexes Pt1-Pt7, with the general formula [{Pt(L)Cl}2(μ-1,5-nphe)](ClO4)2 (1,5-nphe is 1,5-naphthyridine; while L is two ammines (Pt1) or one bidentate coordinated diamine: ethylenediamine (Pt2), (±)-1,2-propylenediamine (Pt3), trans-(±)-1,2-diaminocyclohexane (Pt4), 1,3-propylenediamine (Pt5), 2,2-dimethyl-1,3-propylenediamine (Pt6), and 1,3-pentanediamine (Pt7)), were reported. In vitro cytotoxic activity of these complexes was evaluated against three tumor cell lines, murine colon carcinoma (CT26), murine mammary carcinoma (4T1) and murine lung cancer (LLC1) and two normal cell lines, murine mesenchymal stem cells (MSC) and human fibroblast (MRC-5) cells. The results of the MTT assay indicate that all investigated complexes have almost no cytotoxic effects on 4T1 and very low cytotoxicity toward LLC1 cell lines. In contrast to the effects on LLC1 and 4T1 cells, complexes Pt1 and Pt2 had significant cytotoxic activity toward CT26 cells. Complex Pt1 had a much lower IC50 value for activity on CT26 cells compared with cisplatin. In comparison with cisplatin, all dinuclear Pt1-Pt7 complexes showed lower cytotoxicity toward normal MSC and MRC-5 cells. In order to measure the amount of platinum(ii) complexes taken up by the cells, we quantified the cellular platinum content using inductively coupled plasma mass spectrometry (ICP-QMS). Molecular docking studies performed to evaluate the potential binding mode of dinuclear platinum(ii) complexes Pt1-Pt7 and their aqua derivatives W1-W7, respectively, at the double stranded DNA showed that groove spanning and backbone tracking are the most stable binding modes.

Synthetic method of oxaliplatin

-

Paragraph 0011; 0017; 0022; 0027, (2017/08/31)

The invention discloses a synthetic method of oxaliplatin. The synthetic method comprises the following steps: firstly, taking potassium chloroplatinite and (1R,2R)-1,2-cyclohexanediamine, putting the substances into water, keeping a mixed solution in dark place and reacting the mixed solution under the conditions that the temperature is 35 to 45 DEG C and microwave is 200 to 500W to obtain cis-dichloro(1R,2R)-1,2-cyclohexanediamineplatinum; secondly, dissolving a product obtained in the first step into water, adding silver sulfate, keeping a mixed solution in the dark place, stirring the mixed solution under the conditions that the temperature is 35 to 50 DEG C and microwave is 200 to 400W and then filtering; thirdly, taking filtrate in the second step, adding tetraethylammonium lodide and activated carbon, stirring and filtering; fourthly, taking filtrate in the third step, first adding oxalic acid and Ba(OH)2.8H2O in the stirring process, stirring for 2 to 3 hours under the condition of keeping in the dark place, filtering, and evaporating and refining the filtrate to obtain the oxaliplatin. By using microwave reaction conditions, the efficiency is improved, reaction time is shortened, production period is shortened, and the production cost is reduced; the purity and the yield of a product are higher.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 61848-66-6